Pharmaceutical Executive December 12, 2024
Mike Hollan

The industry is facing an uncertain regulatory landscape in the coming year.

The recent election of Donald Trump as president of the United States is sure to have a significant impact on many industries, including the pharmaceutical and life sciences industries. Whether its actions that will have a direct impact, such as naming Robert F. Kennedy Jr to be head of the Department of Health and Human Services, or indirect impacts, such as his plans to place tariffs on certain goods, the industry is preparing for an uncertain regulatory landscape. Arthur Wong, health care managing director at S&P Global Rankings, spoke with Pharmaceutical Executive about the potential impacts of the election.

Pharmaceutical Executive: How will the expiration of ACA subsidies...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Interview / Q&A, Pharma, Pharma / Biotech, Trends
Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says
Google DeepMind CEO: AI-Designed Drugs Coming to Clinical Trials in 2025
DOJ Accuses Walgreens of Filling Millions of Illegitimate Prescriptions
DOJ sues Walgreens for allegedly filling millions of illegal prescriptions, including opioids
Beyond the stethoscope: the AI-powered revolution and personalized medicine will shape the next era of U.S. health care

Share This Article